AUTHOR=Guselnikov Sergey V. , Baranov Konstantin O. , Kulemzin Sergey V. , Belovezhets Tatyana N. , Chikaev Anton N. , Murasheva Svetlana V. , Volkova Olga Y. , Mechetina Ludmila V. , Najakshin Alexander M. , Chikaev Nikolai A. , Solodkov Pavel P. , Sergeeva Maria V. , Smirnov Alexander V. , Serova Irina A. , Serov Oleg L. , Markhaev Alexander G. , Kononova Yulia V. , Alekseev Alexander Y. , Gulyaeva Marina A. , Danilenko Daria M. , Battulin Nariman R. , Shestopalov Alexander M. , Taranin Alexander V. TITLE=A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants JOURNAL=Frontiers in Immunology VOLUME=15 YEAR=2024 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1442160 DOI=10.3389/fimmu.2024.1442160 ISSN=1664-3224 ABSTRACT=

The COVID-19 pandemic has uncovered the high genetic variability of the SARS-CoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. In vitro, iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape.